Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Periodontal pathogenic bacteria are a specialized group of microorganisms, predominantly anaerobic and Gram-negative, that inhabit the subgingival biofilm and serve as the primary etiological agents of inflammatory periodontal diseases (StatPearls, 2023). The most significant pathogens include the "Red Complex"—Porphyromonas gingivalis, Tannerella forsythia, and Treponema denticola—which are strongly associated with advanced tissue destruction and clinical attachment loss (Socransky et al., 1998; NIH, 2023). These bacteria employ various virulence factors, such as proteases (gingipains) and lipopolysaccharides, to bypass host immune defenses and trigger a chronic inflammatory response that leads to the degradation of the periodontium and alveolar bone (Journal of Oral Microbiology, 2020). Furthermore, these pathogens are implicated in systemic health issues, including cardiovascular disease and diabetes, due to their ability to enter the bloodstream and promote systemic inflammation (American Academy of Periodontology, 2021). Therapeutic interventions aim to eradicate or suppress these populations using mechanical scaling and root planing often combined with antimicrobial agents like metronidazole, amoxicillin, or local-delivery doxycycline (Cochrane Database, 2020). These drugs work by inhibiting essential bacterial processes such as cell wall synthesis or protein translation, thereby reducing the bacterial burden and allowing for tissue healing.
Inhibition of bacterial cell wall synthesis, protein synthesis, or DNA replication; disruption of bacterial cell membrane and biofilm integrity
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Periodontal pathogenic bacteria.